Navigation Links
SuperGen's MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib
Date:4/14/2008

Data support MP-470's role in overcoming erlotinib resistance

DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at the 2008 AACR Annual Meeting that MP-470 effectively sensitizes prostate and breast cancer cells to erlotinib (Abstract No. 671).

Entitled, "Inhibition of erlotinib resistance on HER-family tyrosine kinases by combination with MP-470, a multi-targeted TK inhibitor in prostate and breast cancer," the poster highlights data indicating that the combination of MP-470 and erlotinib inhibits the binding of the p85 subunit of PI3K, and has a greater impact than either agent alone in reducing phosphorylation of Akt, ERK1/2, EGFR/HER1, HER2/Neu, and HER3.

"These data build upon previous results showing that MP-470 exhibits anti-tumor activity in breast and prostate cancer cells," said Dr. David Bearss, SuperGen's Vice President and Chief Scientist. "The fact that MP-470 in combination with erlotinib effectively suppressed the HER pathway suggests that concurrent administration of both compounds could represent a new treatment for prostate and breast cancers. We will continue to explore this synergy as we develop further MP-470."

Copies of the 2008 AACR Annual Meeting poster presentations will be available in the pipeline section of SuperGen's Web site http://www.supergen.com.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development an
'/>"/>

SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
3. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Prostate Cancer Treatment Centre Receives Funding for Clinical Trials
11. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 26, 2015 Research and Markets( http://www.researchandmarkets.com/research/nt9zlx/asia_pacific ) ... Mammography Market - Growth, Trends And Forecasts (2014 - ... Mammography is a detailed type of imaging that customs ... exam, called a mammogram, is used to support in ... women. An x-ray (radiograph) is a noninvasive medical test ...
(Date:5/27/2015)... Donatelli, a senior marketing associate with the animal health division of Eli ... a healthcare setting in Bangkok, Thailand , will be ... need with respect and dignity is the guiding star for me and ... in a LillyPad blog . Donatelli and Lilly colleagues ... Colombia , France , Ukraine ...
(Date:5/27/2015)... May 25, 2015 Research and Markets ... addition of the "2015 Strategies in the ... offering. This comprehensive five-country report contains ... help current suppliers and potential market entrants identify ... coagulation testing market during the next five years. ...
Breaking Medicine Technology:Asia Pacific Mammography Market Trends and Forecasts 2015-2019 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 2Lilly Sends Employees to Serve in Vulnerable Communities around the World 3European Coagulation Testing Market Strategies 2015 2
... TARRYTOWN, N.Y., Feb. 28, 2011 Regeneron Pharmaceuticals, Inc. ... a second Phase 3 study (PRE-SURGE 2) in gout ... and all secondary study endpoints. The primary endpoint was ... 16-week treatment period. Patients who received ARCALYST at a ...
... MYL ) today announced that its subsidiary Matrix ... and Drug Administration (FDA) for its Abbreviated New Drug Application ... 400 mg, the generic version of Pfizer,s Neurontin ® ... Gabapentin Capsules had U.S. sales of approximately $300 ...
Cached Medicine Technology:ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 2ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 3ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 4ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 5ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 6ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 7ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 8ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 9ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy 10
(Date:5/28/2015)... 28, 2015 Orem, UT—Dymicron, Inc., (dymicron.com) ... using their unique Triadyme-C cervical total disc replacement device. ... William D. Smith at the American Institute of Minimally ... are responding well to the implantation of the Dymicron ... Spine Center and Chief of Neurosurgery for the University ...
(Date:5/28/2015)... Career Step, an online provider of ... that Career Step Executive Vice President Mike Hodgson will ... presented by ICD10monitor in conjunction with Kimberly J. Carr ... and Ms. Carr will be discussing the importance of ... , “We have worked closely with HRS on a ...
(Date:5/28/2015)... Aureus Medical Group (web: aureuslocumtenens.com), a national ... announced that it will participate as an exhibitor at ... to be held June 9-14, 2015 in New Orleans, ... opportunities, and exhibits with products and services. , ... will be available to speak with attendees about its ...
(Date:5/28/2015)... 28, 2015 Atlanta-based Thrive Senior Living ... ground this summer on an innovative new Assisted Living ... engagement and connectivity in a unique, resort-like environment, Thrive ... technology and southern hospitality to create a distinctive experience ... unit community will feature luxuriously appointed resident apartments, a ...
(Date:5/28/2015)... 28, 2015 Peggy J. Lynam, PT, DPT, ... the American Physical Therapy Association House of Delegates for the ... their Delegate Assembly. This will be her second term. ... as coordinator and principle spokesperson for the Chapter delegation and ... Directors or Delegate Assembly may direct the Chief Delegate to ...
Breaking Medicine News(10 mins):Health News:Dymicron, Inc., Announces the First Human Implantation of their Triadyme-CTM Cervical Total Disc Replacement Device in Cyprus 2Health News:Career Step and HRS Hosting June 4 ICD10monitor Webinar on the Importance of Auditing and Physician Training for ICD-10 Success 2Health News:Career Step and HRS Hosting June 4 ICD10monitor Webinar on the Importance of Auditing and Physician Training for ICD-10 Success 3Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the American Association of Nurse Practitioners’ 2015 National Conference 2Health News:Thrive Announces Innovative New Senior Living Community in Huntsville, AL 2
... COLUMBUS, Ga., June 1 Aflac Incorporated,announced today that ... president and deputy chief financial officer. Susan R. Blanck ... Japan. Both promotions are,effective June 1, 2008., Durant ... comptroller of,Aflac Incorporated. He was with Aflac for 10 ...
... lost, son in 1994, volunteered for AIDS Action and raised more than $250,000 ... ... Today,s 23rd AIDS Walk Boston,attracted more than 20,000 participants -- the most ... runners,over last year, with 600 runners in The Larry Kessler 5K Run -- ...
... malignancies, study suggests , , SUNDAY, June 1 (HealthDay News) ... have value in helping to prevent lung cancer. , ... inhibitor on the U.S. market, may reduce levels of ... team presented its findings Sunday at the American Society ...
... patients on chemotherapy , , SUNDAY, June 1 (HealthDay News) ... effects of treatment for head and neck cancer patients ... acupuncture. , A new study found significant reductions in ... neck dissection in patients receiving acupuncture. , "Although further ...
... Adults who survived childhood Hodgkins Lymphoma should ... according to researchers from Wake Forest University Baptist ... annual meeting of the American Society of Clinical ... pediatric oncologist, said a 26-center study of 1,927 ...
... finds , , SATURDAY, May 31 (HealthDay News) -- ... survival in women with advanced breast cancer, new ... adding Avastin (bevacizumab) to the chemotherapy drug Taxol ... doubled progression-free survival. , Avastin is already approved ...
Cached Medicine News:Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 2Health News:Martin Durant Promoted to Executive Vice President and Deputy CFO; Sue Blanck Promoted to First Senior Vice President of Aflac Japan 3Health News:23rd AIDS Walk Boston Draws Five-Year Record-Setting 20,000+ Participants, Doubles Runners to 600 and Raises $1.2 Million 2Health News:23rd AIDS Walk Boston Draws Five-Year Record-Setting 20,000+ Participants, Doubles Runners to 600 and Raises $1.2 Million 3Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 2Health News:Celebrex May Reduce Levels of Lung Cancer Biomarker 3Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 2Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 3Health News:Survivors of childhood Hodgkin's lymphoma at higher risk of future health problems 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 3
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: